The gut microbiota : A predisposing factor in obesity, diabetes and atherosclerosis
(2016) p.351-359- Abstract
The cluster of pathologies comprising the metabolic syndrome (MetS) includes increased waist circumference, hyperglycemia, elevated blood pressure and hyperlipidemia. With time, these conditions present a major risk of developing obesity, type 2 diabetes and atherosclerosis. Fecal microbiota transplant (FMT) experiments performed in mice have given an intriguing foundation for a microbial-based therapy of obesity in humans. In the years 2004 - 2009, Gordon and colleagues presented ground-breaking studies on the role of the gut microbiota in host energy metabolism and proposed the hypothesis that obesity alters the composition of bacteria in the gut. Lipopolysaccharides (LPS) is a component of Gramnegative bacteria cell walls and is... (More)
The cluster of pathologies comprising the metabolic syndrome (MetS) includes increased waist circumference, hyperglycemia, elevated blood pressure and hyperlipidemia. With time, these conditions present a major risk of developing obesity, type 2 diabetes and atherosclerosis. Fecal microbiota transplant (FMT) experiments performed in mice have given an intriguing foundation for a microbial-based therapy of obesity in humans. In the years 2004 - 2009, Gordon and colleagues presented ground-breaking studies on the role of the gut microbiota in host energy metabolism and proposed the hypothesis that obesity alters the composition of bacteria in the gut. Lipopolysaccharides (LPS) is a component of Gramnegative bacteria cell walls and is pro-inflammatory through activation of Toll-like receptor 4 (TLR4) on antigen-presenting cells located both in the gut and in other tissues in the body. Diabetes mellitus (DM) presents in two major forms: type I and type II, characterized by vastly different molecular events leading up to malfunction of glucose homeostasis.
(Less)
- author
- Fåk, Frida LU
- organization
- publishing date
- 2016-09-22
- type
- Chapter in Book/Report/Conference proceeding
- publication status
- published
- subject
- keywords
- Atherosclerosis, Diabetes mellitus, Fecal microbiota transplant, Glucose homeostasis, Gut microbiota, Lipopolysaccharides, Metabolic syndrome, Microbial-based therapy, Obesity, Toll-like receptor 4
- host publication
- The Human Microbiota and Chronic Disease: Dysbiosis as a Cause of Human Pathology
- pages
- 9 pages
- publisher
- Wiley
- external identifiers
-
- scopus:85018685700
- ISBN
- 9781118982907
- 9781118982877
- DOI
- 10.1002/9781118982907.ch23
- project
- ANTIDIABETIC FOOD CENTRE
- language
- English
- LU publication?
- yes
- id
- 34b4efb3-4503-4d0e-9ea9-4beaecde9bc1
- date added to LUP
- 2017-05-24 14:30:28
- date last changed
- 2024-02-29 15:41:56
@inbook{34b4efb3-4503-4d0e-9ea9-4beaecde9bc1, abstract = {{<p>The cluster of pathologies comprising the metabolic syndrome (MetS) includes increased waist circumference, hyperglycemia, elevated blood pressure and hyperlipidemia. With time, these conditions present a major risk of developing obesity, type 2 diabetes and atherosclerosis. Fecal microbiota transplant (FMT) experiments performed in mice have given an intriguing foundation for a microbial-based therapy of obesity in humans. In the years 2004 - 2009, Gordon and colleagues presented ground-breaking studies on the role of the gut microbiota in host energy metabolism and proposed the hypothesis that obesity alters the composition of bacteria in the gut. Lipopolysaccharides (LPS) is a component of Gramnegative bacteria cell walls and is pro-inflammatory through activation of Toll-like receptor 4 (TLR4) on antigen-presenting cells located both in the gut and in other tissues in the body. Diabetes mellitus (DM) presents in two major forms: type I and type II, characterized by vastly different molecular events leading up to malfunction of glucose homeostasis.</p>}}, author = {{Fåk, Frida}}, booktitle = {{The Human Microbiota and Chronic Disease: Dysbiosis as a Cause of Human Pathology}}, isbn = {{9781118982907}}, keywords = {{Atherosclerosis; Diabetes mellitus; Fecal microbiota transplant; Glucose homeostasis; Gut microbiota; Lipopolysaccharides; Metabolic syndrome; Microbial-based therapy; Obesity; Toll-like receptor 4}}, language = {{eng}}, month = {{09}}, pages = {{351--359}}, publisher = {{Wiley}}, title = {{The gut microbiota : A predisposing factor in obesity, diabetes and atherosclerosis}}, url = {{http://dx.doi.org/10.1002/9781118982907.ch23}}, doi = {{10.1002/9781118982907.ch23}}, year = {{2016}}, }